Nasdaq has rescheduled hearing for mid-June, decision expected by mid-July

Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, today announced that it has received notice from Nasdaq that the date of its hearing before the Nasdaq Listing Qualifications Panel (the “Panel”) has been rescheduled by Nasdaq from mid-May to mid-June, and therefore the Company now expects a decision from the Panel in mid-July.

At the hearing, the Company will present its plan for regaining compliance with the listing requirements and request an extension of time within which to do so. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an extension of up to 180 calendar days from the date of the Staff Determination Letter; however, there can be no assurance that the Panel will grant the Company’s request for an extension.

“As we have said before, we have two possible ways to return to compliance,” said Jeff Rona, Chief Financial Officer of Great Basin Scientific. “’The first would be have our Market Capitalization rise above $35 million for 10 consecutive business days. The other would be to achieve positive stockholders’ equity of $2.5 million. We intend to pursue both paths over the coming six months and we remain optimistic that the Panel will grant us the added time needed to execute our plan and come into continued listing compliance.”

For additional information on the hearing process the Company refers investors to the Nasdaq FAQ found at: https://listingcenter.nasdaq.com/Material_Search.aspx?mcd=LQ&cid=107&sub_cid=32&years=0&criteria=1&materials

About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease.

Forward-Looking Statements

This press release includes forward-looking statement regarding events, trends and business prospects, which may affect our future operating results and financial position, including statements regarding the Company expectation of requesting a hearing with the Panel, the anticipated timing of the hearing and determination of the Panel, and the Company’s ability to regain compliance with NASDAQ listing requirements. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history or losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2015. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

Media:ICRKate Ottavio Kent, 203-682-8276Kate.Ottavio-Kent@icrinc.comorInvestor Relations:CorProminenceScott Gordon, 516-222-2560gbinfo@corprominence.comorICRDavid Clair, 646-277-1266David.Clair@icrinc.com